Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Poised To Be First To Market With A PD-1 For First-Line Lung Cancer

Executive Summary

Merck’s Keytruda improved progression-free survival and overall survival in previously untreated non-small cell lung cancer patients in the highly-anticipated KEYNOTE-024 trial, all but guaranteeing a rapid FDA approval in the indication.

Advertisement

Related Content

Was PD-L1 Test To Blame For Failure Of Bristol's Opdivo In '026 Trial?
Was PD-L1 Test To Blame For Failure Of Bristol's Opdivo In '026 Trial?
It’s Here: Merck’s Keytruda Cleared For First-Line Lung Cancer
Genentech’s Tecentriq Stakes New Claim With FDA Lung Cancer Approval
Merck's Keytruda Chemo-Combo Data Has Big Implications For Future Of Immuno-Oncology
Opdivo Fallout: Rivalry In PD-1 Market To Continue, More Trials Could Mean More Failures
Merck Defends Its Offensive Strategy For Keytruda
What's Next For Bristol's Opdivo/Yervoy Combination
Early Tecentriq OK Gives Roche/Genentech Jump On PD-L1 Bladder Cancer Market
Merck Is Finding PD-L1 Testing Is Helping Keytruda

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC065434

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel